Company: CRNX
Filing Date: 2025-04-23
Form Type: DEF 14A
Source: 0000950170-25-057452
Chunk: 40

Company: Crinetics Pharmaceuticals, Inc.
Filing Date: 2025-04-23
Form: DEF 14A
Chunk 40
---
. Scott Struthers, Ph.D. |     |  62 |     | President, Chief Executive Officer and Director |
| Tobin Schilke             |     |  50 |     | Chief Financial Officer                         |
| Stephen Betz, Ph.D.       |     |  59 |     | Chief Scientific Officer                        |
| Dana Pizzuti, M.D.        |     |  69 |     | Chief Medical and Development Officer           |
| Jeff Knight               |     |  54 |     | Chief Operating Officer                         |
| Isabel Kalofonos          |     |  54 |     | Chief Commercial Officer                        |

The biography of R. Scott Struthers, Ph.D. can be found under “Proposal 1: Election of Directors.” Tobin “Toby” Schilke has served as our Chief Financial Officer since February 2025. Prior to joining Crinetics, Mr. Schilke served as chief financial officer at Revance Therapeutics, Inc. from November 2018 to February 2025, where he oversaw finance, investor relations, IT, and technical operations for a public company, supporting the transformation to a commercial company with two product launches. From 2016 to 2018, Mr. Schilke served as Chief Financial Officer at Achaogen, Inc., where he built out the financial planning and analysis, accounting, procurement, information technology, and facilities management functions. Earlier in his career, he spent more than a decade in increasing roles of responsibility at Roche/Genentech in corporate development, commercial finance, marketing and global operations. Mr. Schilke holds a bachelor’s degree in chemical engineering from Lafayette College, a master’s degree in chemical engineering from the University of California, Berkeley, and a master’s degree in business administration from Cornell University. Stephen F. Betz, Ph.D. is a co-founder and has served as our Chief Scientific Officer since October 2021 and served as our Vice President of Biology from December 2009 to October 2021. Previously, from 2003 to 2009, Dr. Betz worked at Neurocrine Biosciences, Inc., as Director of Endocrinology and Metabolism, where he worked on the discovery and development of GnRH receptor antagonists and nonpeptide modulators of other endocrine targets. Prior to Neurocrine, from 2001 to 2003, Dr. Betz led laboratory efforts at GeneFormatics,